Cancer Molecular Imaging, Nanotechnology and Theranostics Program

Print

Dr. Caius Radu Dr. Jeffrey Zink

Director
Johannes Czernin, M.D.
Contact via email

Co-Director
Caius Radu, Ph.D.
Contact via email

Co-Director
Jeffrey Zink, Ph.D.
Contact via email


Overview

The Cancer Molecular Imaging, Nanotechnology, and Theranostics (CMINT) research program advances translational imaging, nanoparticle design and delivery, and theranostics to improve cancer patient outcomes and moves discoveries from preclinical and clinical applications. The research program is highly interactive and transdisciplinary, and brings together 45 faculty members from four UCLA schools and partner institution Caltech, representing 16 basic and clinical departments. Its members have diverse and complementary expertise in an extensive range of disciplines including biology, nuclear medicine, physics, nanotechnology, urology, radiology, radiation oncology, drug development, engineering, image reconstruction, chemistry, radiochemistry and animal models of disease.


Goals

The four specific aims of the CMINT research program are:

  • Development of instrumentation, analytical tools, and novel molecular imaging approaches
  • Imaging immune responses and responses to immunotherapy
  • Nanotechnology-based imaging and therapeutic delivery systems
  • Translation of diagnostic and theranostics approaches into the clinic

Meetings and events

  • Participation in the UCLA Jonsson Comprehensive Cancer Center seminar series that features invited outside and local faculty
  • Weekly research program meeting
  • Quarterly presentations featuring SOMI (Scholars in Oncologic Molecular Imaging) postdoctoral fellows and faculty discussions
  • Seminar series with external speakers (in collaboration with Crump Institute for Molecular Imaging and California NanoSystems Institute at UCLA)
  • Quarterly research program scientific exchange dinners
  • Semi-annual, inter-programmatic symposia on nanotechnology in cancer

Leadership

Director Dr. Johannes Czernin is Professor and Vice Chair of the UCLA Department of Molecular and Medical Pharmacology. Czernin serves as Chief of the Ahmanson Translational Imaging Division (ATID), that includes the UCLA nuclear medicine clinical service, the biomedical cyclotron operation, a preclinical imaging center, a cancer biology and drug development group (Radu) as well as a radiochemistry group. He has more than 25 years of experience in molecular imaging, and held national and international leadership positions including president of the Academy of Molecular Imaging). He serves as Editor-in-Chief of the Journal of Nuclear Medicine. He is a co-founder of Sofie Biosciences Inc. and Trethera Therapeutics, UCLA spin-offs that translate technology and targeted drugs to the market. Czernin has established a translational research program that links laboratory studies of cellular uptake of radioactive metabolites or ligands, preclinical evaluation of specific molecular imaging probes in small animals, and clinical evaluation of new radiotracers for molecular imaging of cancer patients. He also recently established a successful translational theranostics program. His strength is in translating preclinical research into clinical applications, and he has designed and conducted numerous past and ongoing clinical trials.

Co-director Dr. Caius Radu is Professor and Vice-Chair of the UCLA Department of Molecular and Medical Pharmacology. He serves as associate director of ATID and heads their cancer biology and drug development groups. His work elucidates therapy resistance mechanisms in cancer and identifies cancer liabilities that can be exploited using pharmacologic and genetic approaches. Radu embeds diagnostics and therapeutics in tumor biology resulting in identification and pharmacologic targeting of cancer liabilities. He closely collaborates with Czernin to define unmet clinical needs that are addressed from the cellular to the small animal and finally to the clinical level. He has established a successful drug development program and uses imaging probes as predictive biomarkers for treatment response. Radu is also a co-founder of Sofie Biosciences Inc. and Trethera Therapeutics.

Co-director Dr. Jeffrey Zink is a Distinguished Professor in the UCLA Department of Chemistry and Biochemistry. He is a pioneer of multifunctional mechanized nanoparticle synthesis and biomedical applications, and with his collaborators, create particles that are biocompatible and deliver hydrophobic drugs and siRNA into cells and tumors in vivo. His studies brought worldwide attention to the therapeutic properties of mesoporous silica nanoparticles (MSNPs) as drug delivery systems. Additional collaborations have proudced a creative method to modify the vasculature for improved drug delivery in pancreatic ductal adenocarcinoma, the engineering of siRNA-loaded nanoparticles to inhibit TWIST protein and block the epithelial-to-mesenchymal transition in breast and ovarian cancers, and the development of novel nanoparticle-based magnetic resonance image guided therapy.


Upcoming events

The following list is for upcoming events and seminars of notable interest to the Cancer Molecular Imaging, Nanotechnology and Theranostics Program and its members. This calendar is updated automatically.

For a list of all upcoming JCCC events (including other research programs, patients and survivors, and the UCLA Jonsson Cancer Center Foundation), please visit the Events Calendar.

UCLA Jonsson Comprehensive Cancer Center 2021 Retreat

 Image promoting the 2021 UCLA Jonsson Comprehensive Cancer Center Inaugural Retreat

We are excited to announce the rescheduling of the UCLA Jonsson Comprehensive Cancer Center’s Inaugural Retreat, which will now take place virtually on May 13, 2021!

Registration is now open! Please visit our online registration site and register now!


About the Retreat

Image of cancer researcher Victor Velculescu
Keynote speaker Dr. Victor E. Velculescu

The keynote speaker for the event is Dr. Victor E. Velculescu, Professor of Oncology, Pathology and Medicine and Co-Director of Cancer Genetics and Epigenetics at the Sidney Kimmel Comprehensive Cancer Center.

The all-day event will bring together the broader cancer research community from across UCLA, including faculty researchers, physicians, physician-scientists, students, post-docs and allied health professionals.

This virtual retreat is an opportunity for a wide array of individuals working to accelerate discoveries that prevent and cure cancer to share progress and accomplishments, discuss challenges and future directions, learn about resources available at the Cancer Center, and develop and strengthen collaborations.

Planned activities include sessions comprised of talks on a variety of topics and an exhibitor’s room with virtual booths on UCLA cancer research-related services available to you.


How to register

Registration is required and is now open. Please visit our online registration site to reserve your spot.

We look forward to seeing you at the retreat!


Agenda

7:30 a.m.

Lobby & Exhibit Hall open

8:00 a.m.

Welcome & Opening Remarks
Michael Teitell, MD, PhD
Kelsey Martin, MD, PhD

SESSION I

8:15 a.m.

Development of Imatinib and Ibrutinib: Historical Perspective on Targeted Therapy and the JCCC
Owen Witte, MD

8:45 a.m.

Variability in Cancer Diagnosis: Implications, Challenges, and the Promise of AI
Joann Elmore, MD, MPH

9:05 a.m.

The Simms/Mann Center for Integrative Oncology: A community based approach to whole person care
Kauser Ahmed, PhD

9:25 a.m.

SPOREs: Progress and Opportunities

  • UCLA SPORE in Prostate Cancer
  • UCLA SPORE in Brain Cancer

Rob Reiter, MD
Linda Liau, MD, PhD, MBA

9:55 a.m.

Coffee break

SESSION II

10:10 a.m.

What Can The Cancer Center Do For “U”?

  • JCCC Funding Mechanisms: Seed Grants and More
  • JCCC Shared Resources Overview
  • JCCC Activities and Support Services
  • UC-Cancer Consortium

Heather Christofk, PhD
Melissa Fitzmaurice Neligan, MPH, CRA
Zoran Galic, PhD
Michael Teitell MD, PhD

10:30 a.m.

Advancing Science to Address Pressing Cancer Needs in our Communities
Roshan Bastani, PhD
Beth Glenn, PhD
Alison Herrmann, PhD

10:55 a.m.

Early Detection of Cancer Using Noninvasive Liquid Biopsies
Victor E. Velculescu, MD, PhD

12:00 p.m.

Lunch Break and Networking
Informational Booths open for viewing in Exhibit Hall

SESSION III

12:30 p.m.

Engineering Next‐Generational CAR‐T Cells for Cancer Immunotherapy
Yvonne Chen, PhD

1:00 p.m.

The Evolutionary Origins of Cancer Lethality
Paul Boutros, PhD, MBA

1:30 p.m.

Coffee break

SESSION IV

1:40 p.m.

Development of Breast Cancer Therapies: Herceptin, palbociclib
Dennis Slamon, MD, PhD

2:10 p.m.

Fighting Melanoma with the Immune System Melanoma
Antoni Ribas, MD, PhD

2:40 p.m.

Entrepreneurship and the Business of Science
Arie Belldegrun, MD
Christi Shaw, MBA, CEO of Kite Pharma
Craig Gordon, MD, Partner, Capital Research Global Investors
David Chang MD, PhD, CEO of Allogene Pharma in SF
Helen Kim, MBA, SMD of Vida Ventures in SM


3:25 p.m.

Closing Remarks
Michael Teitell, MD, PhD

3:30 p.m.

Retreat ends

Return to full list >>